Holen Sie sich die Stockscreener-App
12.91
0.39%
-0.05
Carlsmed Inc Aktie (CARL) Neueste Nachrichten
Carlsmed initiated with Buy at Truist on business potential - MSN
Carlsmed Q2 2025 revenue up 99% to USD 12.1M - Medical Buyer
Carlsmed, Inc.: Strong Financial Performance and Growth Potential Justify Buy Rating - TipRanks
Carlsmed stock rating reiterated at Buy by Goldman Sachs on growth outlook - Investing.com
Carlsmed, Inc.: Strong Performance and Promising Growth Prospects with Upcoming Product Launch - TipRanks
Carlsmed Reports Strong Growth in Q2 2025 Earnings - TipRanks
Carlsmed 2025 Q2 Earnings Strong Revenue Growth Despite Widening Net Loss - AInvest
Carlsmed: A High-Growth AI-Driven MedTech Play in Spine Surgery - AInvest
UPDATECarlsmed® Reports Second Quarter 2025 Financial Results - The Manila Times
Earnings call transcript: Carlsmed’s Q2 2025 revenue surges, stock rises - Investing.com
Carlsmed Q2 Loss Narrows, Revenue Rises - MarketScreener
Carlsmed reports second quarter 2025 financial results - MarketScreener
Carlsmed® Q2 2025 Financial Performance: Assessing Long-Term Growth Potential in the AI-Driven Spine Surgery Revolution - AInvest
CARLSMED, INC. SEC 10-Q Report - TradingView
Carlsmed, Inc.'s Q2 2025 Performance and Strategic Momentum: A Disruptive Force in AI-Driven Spine Surgery - AInvest
Carlsmed® Reports Second Quarter 2025 Financial Results - MarketScreener
99% Growth: AI Spine Surgery Pioneer Carlsmed Hits $12.1M Revenue, Expands into Cervical Procedures - Stock Titan
Carlsmed CARL 2025Q2 Earnings Preview Upside Potential on AI-Driven Spine Solutions - AInvest
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Truist Securities initiates coverage on Carlsmed stock with Buy rating By Investing.com - Investing.com Australia
Why Is Carlsmed Stock Gaining Monday?Carlsmed (NASDAQ:CARL) - Benzinga
AI medtech firm Carlsmed prices $100.5M IPO - MSN
Truist Initiates Buy on Carlsmed with Focus on Business Growth Potential - AInvest
Carlsmed initiated with Buy at Truist on business potential (CARL) - Seeking Alpha
BofA Securities Initiates Coverage on Carlsmed With Buy Rating, $16 Price Target - MarketScreener
This Synaptics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Goldman Sachs Initiates Coverage on Carlsmed With Buy Rating, $19 Price Target - MarketScreener
Carlsmed initiated with a Buy at BTIG - TipRanks
Truist Securities initiates coverage on Carlsmed stock with Buy rating - Investing.com
Truist Initiates Carlsmed at Buy With $18 Price Target - MarketScreener
Piper Sandler initiates coverage on Carlsmed with an Overweight rating, PT of $18. - AInvest
Buy Rating for Carlsmed: Innovative Aprevo Technology and Strong Growth Projections Justify Premium Valuation - TipRanks
Carlsmed stock initiated with Buy rating at BTIG on customized implant tech - Investing.com
Carlsmed stock initiated with Buy rating at BTIG on customized implant tech By Investing.com - Investing.com South Africa
Carlsmed initiated with an Overweight at Piper Sandler - TipRanks
Piper Sandler initiates Carlsmed stock with Overweight rating on custom implant potential - Investing.com India
Carlsmed's Personalized Spine Implants Get Significant Reimbursement Advantage - inkl
Goldman Sachs initiates coverage on Carlsmed stock with Buy rating - Investing.com
Goldman Sachs initiates coverage on Carlsmed stock with Buy rating By Investing.com - Investing.com Nigeria
Carlsmed initiated with a Buy at Goldman Sachs - MSN
Carlsmed Stock Down 6% Since IPO But Goldman Bullish And Predicts 35% Upside Potential — Retail Traders Stay Bearish - Stocktwits
AI medtech firm Carlsmed to sell 6.7M shares in IPO - MSN
Carlsmed, Inc. shares fall 2.01% after-hours as it prepares to report Q2 2025 financial results. - AInvest
Carlsmed Inc. to Report Second Quarter 2025 Financial Results on August 28, 2025 - The Manila Times
Carlsmed to report Q2 2025 financial results on Aug 28, 2025. - AInvest
Big Boost for Personalized Cervical Fusion: Add-On Code - Orthopedics This Week
Heartflow raises $317M, pops 66% at market open - BioWorld MedTech
Med-tech funding rebounds modestly to $18B through July - BioWorld MedTech
Carlsmed’s $100.5M IPO fuels 3D printed spinal implants growth - 3D Printing Industry
Carlsmed’s aprevo implants receive CMS NTAP for cervical fusion procedures - TipRanks
Carlsmed’s aprevo® Personalized Interbody Implants Receive CMS New Technology Add-On Payment (NTAP) for Cervical Fusion Procedures - Ortho Spine News
Carlsmed's Aprevo Implants Receive CMS NTAP Approval For Cervical Fusion Procedures Under FY2026 IPPS Final Rule - 富途牛牛
2.53%
0.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):